In the News
Unleashing a Vision
For any other person, being president of one organization – Evidera – and being the chief medical officer of another – PPD – would be a full-time job. Yet, Karen Kaucic, MD excels in both positions.
Predicting extractables and leachables from container stoppers
The authors discuss how data from migration kinetics studies can be used to develop models that predict levels of leachables and extractables at different temperatures and time points.
Advanced therapies: ‘Trip hazards’ on the development pathway
Kirsten Messmer and Richard Dennett discuss the development of advanced therapies and the challenges and complexities of getting them through the developmental pathway, which they call “the trip.”
Pfizer reups PPD deal in a contract research pact spree
PPD strategically positioned to continue supporting Pfizer in its pursuit of breakthroughs that change patients’ lives.
PPD signs new service agreement with Pfizer
Under the agreement, PPD to provide drug development services to advance Pfizer’s portfolio.
PPD inks new deal with Pfizer
Builds on existing relationship, in which PPD has provided expertise in clinical development and laboratory services for Pfizer, including across multiple therapeutic areas.
Moderna enters P3 trials for vaccine, with $483M BARDA push
Moderna is collaborating with PPD to conduct the trials.
Two Wilmington firms involved in Moderna’s Phase 3 COVID vaccine study
PPD contributes a variety of clinical development and laboratory services, including strategic expertise to the study design, patient-enrollment epidemiology modeling and biostatistics.
PPD expands lab test work to boost pandemic vaccine, drug trial research
PPD® Laboratories has developed five new molecular, serology and functional assays designed expressly for COVID-19 vaccine and therapy development programs.